Abstract
A review of recent phase II and III studies in advanced gastric carcinoma is presented. Several combination regimens have been developed with high activity in locally advanced and metastatic disease. Among them are etoposide plus adriamycin plus cisplatin (EAP), etoposide plus 5-fluorouracil plus leucovorin (ELF), continuous infusion 5-fluorouracil plus cisplatin and high dose methotrexate plus 5-fluorouracil plus adriamycin (FAMTX). In locally advanced disease a resectability rate of +/- 50% has been reported with these protocols. So far only FAMTX has demonstrated superiority compared with 5-fluorouracil, adriamycin and mitomycin (FAM), which regimen has been considered 'standard' treatment for many years. Randomized studies in which the other regimens are being more definitely assessed are underway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
